06/11/2022

Chief Scientific Officer of Cullgen Inc. will be speaking at the 30th Annual Meeting of the Japanese Breast Cancer Society

06/11/2022

Beijing Continent enrolls the first subject of pirfenidone capsules Phase III clinical trial for pneumoconiosis

05/24/2022

FY2022 Q1 Analyst Call Q&A Summary

04/15/2022

GNI Group FY2021 Annual General Meeting Q&A Summary

01/31/2022

Frequently Asked Questions Updated File (2022-JAN-31)

01/31/2022

Frequently Asked Questions Updated (2022-JAN-31)

01/04/2022

2022 New Year Greeting

12/29/2021

GNI Group's New Qualification as a Margin Trading Stock

12/28/2021

GNI Group Ltd. Ranks 32nd in 2021 Japan Technology Fast 50

10/26/2021

Berkeley Advanced Biomaterials LLC Exhibited in the U.S. and China Orthopedics Conferences

06/22/2021

Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer

04/16/2021

Ranked in the Financial Times, "High-Growth Companies Asia-Pacific 2021" for the second consecutive year

01/04/2021

New Year Greeting

11/02/2020

Chinese Journal of Tuberculosis and Respiratory Diseases recommended the use of Pirfenidone as an anti-fibrosis therapy for COVID-19 patients in China

08/14/2020

Notice of land acquisition by Beijing Continent Pharmaceutical Co., Ltd.